Monitor the outcome of the April 2026 FDA meeting for guidance on the regulatory path for efzofitimod. The mixed Phase 3 results create uncertainty, but the secondary endpoint benefits may support a potential approval. Cash runway appears sufficient to fund operations into 2027 based on current burn rate.
Price Chart
Executive Summary
aTyr Pharma reported full-year 2025 financial results and provided a corporate update, including the scheduling of an FDA meeting in April 2026 to discuss the Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis. The study missed its primary endpoint but showed clinical benefit across several secondary measures. The company ended 2025 with $80.9 million in cash.
Key Financial Metrics
Key Facts
- Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis did not meet its primary endpoint of change in oral corticosteroid dose at week 48.
- However, 5.0 mg/kg efzofitimod showed statistically significant clinical benefit across multiple secondary endpoints including KSQ-Lung score (p=0.0479), Fatigue Assessment Scale (p=0.0226), and complete steroid withdrawal with KSQ-Lung improvement (p=0.0196).
- Company to meet with FDA in mid-April 2026 to determine the path forward for efzofitimod in pulmonary sarcoidosis.
- Phase 2 EFZO-CONNECT study in systemic sclerosis-related ILD on track to complete enrollment in first half of 2026.
- Ended 2025 with $80.9 million in cash, cash equivalents, restricted cash and investments.
- Full-year 2025 net loss attributable to aTyr was $74.1 million, compared to $64.0 million in 2024.
Financial Impact
Net loss increased from $64.0M in 2024 to $74.1M in 2025, while cash position improved from $75.1M to $80.9M. R&D expenses increased from $54.4M to $60.2M.
Risk Factors
- FDA may not agree on a viable path forward for efzofitimod despite positive secondary endpoints.
- Increased net loss and R&D expenses could pressure cash runway if additional funding is needed.
- Phase 2 EFZO-CONNECT study in SSc-ILD is small (up to 25 patients) and may not provide sufficient data for advancement.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001339970-26-000006 |
| Document: atyr-20260305.htm | 0001339970-26-000006 |
| Document: 0001339970-26-000006-index-headers.html | 0001339970-26-000006 |
| Document: 0001339970-26-000006-index.html | 0001339970-26-000006 |
| Document: 0001339970-26-000006.txt | 0001339970-26-000006 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | Press Release | $0.1717 $0.1534 | ▼ −10.66% | ▼ −10.51% | $0.1530 (−10.89%) |
Oct 7, 2026 19d ago | SC 13G/A | $0.2783 $0.1833 | ▼ −34.14% | ▼ −33.16% | $0.1530 (−45.02%) |
Sep 22, 2026 4w ago | Institutional Cluster | $0.3564 $0.3077 | ▲ +13.66% | ▲ +12.48% | $0.1530 (+57.07%) |
Aug 7, 2026 11w ago | 8-K | $0.5289 $0.5189 | ▲ +1.89% | ▲ +1.84% | $0.1530 (+71.07%) |
Jun 11, 2026 19w ago | Institutional Cluster | $0.4754 $0.4629 | ▼ −2.63% | ▼ −3.06% | $0.1530 (−67.82%) |
Jun 8, 2026 20w ago | 8-K | $0.4556 $0.4433 | ▲ +2.70% | ▲ +5.11% | $0.1530 (+66.42%) |
Jun 1, 2026 21w ago | 8-K | $0.5200 $0.4560 | ▼ −12.31% | ▼ −9.34% | $0.1530 (−70.58%) |
May 15, 2026 23w ago | 8-K | $0.5040 $0.4900 | ▼ −2.78% | ▼ −3.74% | $0.1530 (−69.64%) |
May 15, 2026 23w ago | Press Release | $0.5040 $0.4900 | ▼ −2.78% | ▼ −3.74% | $0.1530 (−69.64%) |
May 11, 2026 24w ago | 8-K | $0.5300 $0.5200 | ▼ −1.89% | ▼ −1.96% | $0.1530 (−71.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers